Table 2 Studies investigating novel biomarkers for anthracycline-induced cardiotoxicity

[4]

Ky (2014)

Breast cancer

78

Human

50

Doxorubicin

60 mg/m²

0, 3, 6, 15 m

NSE^a

–

SE^a

–

[5]

Sawaya (2012)

Breast cancer

81

Human

50 ± 10

Doxorubicin

Epirubicin

240 mg/m²

300 mg/m²

0, 3, 6, 15 m

–

NSE^b

–

–

[24]

Armenian (2014)

Hematologic malignancies

100 (HR)

50 (LR)

Human

13.1

6.1

Variable AC

<300 mg/m²

>300 mg/m²

>10 year

>10 year

NSE

NSE

–

–

[30]

Feola (2009)

Breast cancer

53

Human

55.3

Doxorubicin

60 mg/m²

0, 1, 2, 3 m

NSE

NSE

–

–

[51]

Putt (2015)

Breast cancer

78

Human

48

Doxorubicin

78 mg/m²

0, 3, 6, 15 m

NSE

–

SE

–

[54]

Oliveira-Carvalho (2015)

Breast cancer

59

Human

>18

Doxorubicin

60 mg/m²

0, 3, 6, 9, 12 m

–

–

–

NSE

(miR-208a)

Low dose AC

[55]

Horie (2010)

–

8

Mice

>18

Doxorubicin

20 mg/kg

0, 6, 12, 24 h

–

–

–

SE

(miR-146a)

[56]

Desai (2014)

–

12

Mice

>18

Doxorubicin

3–24 mg/kg

2, 3, 4, 6 weeks

–

–

–

SE

(miR-34a)

[57]

Roca-Alonso (2015)

Breast cancer

5

Mice

Adult

Doxorubicin

15 mg/kg

0, 5 weeks

–

–

–

SE

(miR-30)